CASE REPORT

Locally advanced cholangiolocellular carcinoma successfully treated with curative resection after downsizing chemotherapy: a case report

Yuto Hozaka1*, Yota Kawasaki1, Satoshi Iino1, Tetsuya Idichi1, Yuki Hirase1, Kiyonori Tanoue1, Yuko Matak1, Hiroshi Kurahara1, Kosei Maemura1, Takaaki Arigami1, Shinichi Ueno2, Shoji Natsugoe1 and Takao Ohtsuka1

Abstract

Background: Cholangiolocellular carcinoma (CoCC) is an extremely rare disease comprising less than 1% of all primary malignant liver tumors. No effective treatment other than resection has been established. Herein, we report a case of locally advanced CoCC diagnosed as unresectable, which was successfully treated with curative resection after downsizing chemotherapy.

Case presentation: A 59-year-old Japanese woman with chronic hepatitis B was diagnosed with locally advanced intrahepatic cholangiocellular carcinoma. As it was difficult to perform R0 resection in the local hospital, chemotherapy combined with gemcitabine plus cisplatin was administered every 3 weeks. After a total of 10 courses of chemotherapy over 10 months the tumor was shown to be reduced in size by computed tomography imaging, and she was referred to our department for surgical resection. The effect of chemotherapy was classified as a “partial response” in the response evaluation criteria of solid tumors. After adding one course of chemotherapy, an extended left hepatectomy with resection of the caudate lobe was performed. R0 resection was achieved. Based on the pathological findings, the final diagnosis of CoCC was determined and eight courses of S-1 adjuvant chemotherapy were administered. At 14 months after the operation, the patient was alive without tumor recurrence.

Conclusions: Downsizing chemotherapy with gemcitabine and cisplatin may be an effective treatment strategy in locally advanced CoCC. Further evidence is required to establish an optimal strategy for the treatment of locally advanced CoCC.

Keywords: Cholangiolocellular carcinoma, Cholangiocellular carcinoma, Hepatocellular carcinoma, Locally advanced, Downsizing chemotherapy, Gemcitabine, Cisplatin, S-1

Background

Cholangiolocellular carcinoma (CoCC) is speculated to originate from hepatic progenitor or stem cells [1, 2]. CoCC is an extremely rare disease which comprises less than 1% of primary malignant liver tumors, and surgical resection is the only curative treatment [1]. Compared to intrahepatic cholangiocellular carcinoma (ICC), patients with resectable CoCC tend to have a better prognosis [3]. On the other hand, there are limited reports of unresectable CoCC treatment, and no effective treatment has been established for advanced CoCC. Here, we report a rare case of locally advanced CoCC diagnosed as unresectable, which was successfully treated with...
hepatectomy after downsizing chemotherapy with gemcitabine plus cisplatin.

**Case presentation**

A 59-year-old Japanese woman was admitted to a local hospital for evaluation of a liver mass detected during a regular medical examination. She had chronic hepatitis B and was treated with tenofovir. Abdominal enhanced computed tomography (CT) showed that the tumor had mosaic enhancement, with hepatic segments 4, 5, and 8 measuring $65 \times 61$ mm (Fig. 1a, b). The tumor was attached to the biliary confluence, bifurcation of the anterior–posterior Glissonian, and right portal vein trunk. An invasion to left portal vein trunk, left hepatic duct, and middle hepatic vein was suspected. The possibility of invasion into the right portal vein trunk could not be ruled out. No obvious invasion into the proper and right hepatic arteries was observed. Results showed that the tumor invaded the right anterior hepatic duct and right posterior hepatic duct (RPHD). Magnetic resonance imaging (MRI) showed that the tumor was hypointense on T1-weighted images and hyperintense on T2-weighted images (Fig. 1c). The margin between the tumor and the normal hepatocyte was unclear. $^{18}$F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) showed high FDG uptake with a standardized uptake value (SUV) of 11.15 (Fig. 1d). A liver biopsy of the tumor revealed moderately to poorly differentiated adenocarcinoma that showed a tubular pattern that comprised small variably sized, irregular tubules in the fibrous stroma. On the basis of the above findings, the patient was diagnosed with mass-forming type ICC, T4N0M0 stage IIIB according to the 8th edition of the Union for International Cancer Control (UICC). At the time of diagnosis, indocyanine green (ICG) angiography for evaluating the clearance rate of ICG and technetium-99m-galactosyl human serum albumin (Tc-99m GSA) scintigraphy for
evaluating the liver reserve were not performed; however, according to CT volumetry, the volume of the entire liver was 839 mL, while the volume of the posterior segment was only 200 mL. Curative resection by left trisegmentectomy was anatomically possible; however, if performed, the remnant liver volume and the future liver remnant were predicted to be only 200 mL and 23.8%, respectively. Thus, it was difficult to perform an R0 resection in this patient. Chemotherapy combined with gemcitabine (GEM 1000 mg/m², days 1 and 8) plus cisplatin (CDDP 25 mg/m², days 1 and 8) (GC) was administered every 3 weeks. There were no serious adverse events during the course of chemotherapy. CT was performed once every 3–4 courses, and it was confirmed that the tumor was gradually reducing in size.

After a total of 10 courses of combination chemotherapy over 10 months, she was referred to our department for resection. Physical examination upon admission was normal. Hepatitis C virus antibodies were negative. Hepatitis B virus surface antigen and core antibody were positive. The serum tumor markers at the time of admission to our hospital were normal as follows: prothrombin induced by vitamin K absence or antagonist-II, 16 mAU/mL; α-fetoprotein, 2.6 ng/mL; carbohydrate antigen 19–9, 13.0 U/mL. Other laboratory results were normal. Her indocyanine green retention rate at 15 min (ICGR15) was 5.0%. According to the Child–Pugh classification, her liver function was stage A. She had grade A liver damage. Tc-99m GSA scintigraphy revealed the following results for the clearance index (HH15) and the receptor index (LHL5)—HH15: 0.544 (normal level > 0.5) and LHL15: 0.931 (normal level > 0.9). Thus, it was concluded that the liver reserve was preserved.

The size of the primary tumor had decreased to 38 × 35 mm (42% reduction). The tumor was close to the hilar plate and bifurcation of the anterior–posterior Glissonian, but farther than before chemotherapy on CT and MRI images (Fig. 2a–c). We considered that the tumor was unlikely to infiltrate the B8 and B5 levels of bile ducts and RPHD. FDG-PET/CT revealed that FDG uptake of the tumor had decreased (SUV max: 6.5) (Fig. 2d). Although the diagnosis after chemotherapy did

![Fig. 2](https://example.com/fig2.png)
not change the T4N0M0 stage IIIB (according to UICC), the effect of chemotherapy was classified as a “partial response” in the response evaluation criteria in solid tumors (RECIST). On the basis of the above findings, if extended left hepatectomy with resection of the caudate lobe could be performed (because we believed that the tumor was unlikely to infiltrate the B8 and B5 levels of the bile ducts and RPHD), we determined that a radical resection was possible. If extended left hepatectomy with resection of the caudate lobe was performed after chemotherapy, the entire liver volume (as measured by CT volumetry), remnant liver volume, and future liver remnant were predicted to be 857 mL, 436 mL, and 50.8%, respectively. To predict the remnant liver function, our facility uses the KGSA value (i.e., the ICG clearance rate using galactosyl), and the remnant KGSA (KGSA value \times functional rate of the remnant liver), as reported by Okabayashi et al. [4]. If the remnant KGSA is 0.05 or more, it is used as an index for favorable post-hepatectomy liver function. In this case, the remnant KGSA was 0.079, and it was determined that an extended left hepatectomy with caudate lobe resection was possible. After adding one course of chemotherapy, extended left hepatectomy with resection of the caudate lobe, resection of the extrahepatic bile duct, and local-regional lymphadenectomy of the hepatoduodenal ligament were performed (Fig. 3). Biliary reconstruction was performed with bilioenteric anastomosis in the B5, B8, and RPHD.

The surgical specimens showed a whitish solid tumor of the mass-forming type, measuring 4.5 × 3.5 cm in size (Fig. 4). Pathological examination of the specimens revealed a hyalinized scar tissue with necrosis that comprised most part of the tumor, and proliferation of the tumor cells in a small tubular or cord-like pattern (with a slit-like lumen) peripherally around the scar. Small tubules were composed of cuboidal tumor cells, which have round nuclei and scant cytoplasm. An irregular anastomosing pattern was observed frequently. Although the tumor was predominantly replaced by the hyalinized scar (which probably reflected the effect of chemotherapy), the tumor cells that had proliferated peripherally around the scar were composed of a small

Fig. 3 Operation findings. This image shows the operative findings after extended left hepatectomy with resection of the caudate lobe, resection of the extrahepatic bile duct, and local-regional lymphadenectomy of the hepatoduodenal ligament. B5 (white arrow), B6a (blue arrow), B6c (yellow arrow), and right posterior bile duct (green arrow), were reconstructed by bilioenteric anastomosis.
ductular component intermixed with a cord-like structure. A large duct-type component with mucin-secreting glands, which is typically seen in ICC, was not observed in the current case (Fig. 5a, b). Immunohistochemically, the tumor cells were positive for EMA and CD56 (NCAM). Based on the above findings, the tumor was diagnosed as a CoCC. Approximately one-third of the tumor was composed of viable tumor cells. The surgical margin was 1 mm, and R0 resection was achieved. Lymph nodes showed no metastasis.

Although mild bile leakage was observed during the postoperative course, bile leakage was discontinued after conservative treatment, and the patient was discharged on the 44th postoperative day. Adjuvant chemotherapy performed eight courses (4-week administration and 2-week withdrawal) of S-1 (TS-1; tegafur, gimeracil, oteracil potassium), at 100 mg/body per day. Approximately 14 months after the operation, abdominal CT and PET/CT showed no signs of tumor recurrence.
CoCC was first reported by Steiner and Higginson in 1959 and is more likely to occur in cases of chronic hepatitis [1, 2]. There are a few reports that show chemotherapy is effective for advanced CoCC; however, there is no established choice of chemotherapy [5, 6]. Therefore, focusing on the current case, we discuss three points in published literature using the terms “cholangiolocellular carcinoma” and “chemotherapy” between 1950 and October 2020. To the best of our knowledge, there have been three reports of advanced CoCC in which radical surgery was performed after chemotherapy, including the current case (Table 1) [6, 13]. With the exception of the current case, systemic chemotherapy with gemcitabine alone was administered in one patient, and chemotherapy combined with gemcitabine plus cisplatin via hepatic arterial infusion was administered in one patient. In one case of hepatic arterial infusion therapy, the tumor size was almost unchanged before and after chemotherapy. Another case with gemcitabine monotherapy did not describe the tumor size after chemotherapy. The current case was initially diagnosed with unresectable ICC, and GC was administered, according to the ABC-02 trial. The ABC-02 trial has shown that compared to gemcitabine alone, GC significantly improved overall survival for advanced biliary tract cancer (BTC) including ICC in 2010 [14]. In addition, there is a report of a group of cases in which conversion surgery could be performed for unresectable BTC after the use of GC [15]. As mentioned above, GC is an effective treatment, but there are some cases in which the effect is poor. The 2018 October European Society for Medical Oncology (ESMO) reported the results of a randomized phase III comparative study on gemcitabine, cisplatin plus S-1 (GCS) versus GC for advanced BTC. The median overall survival of the GCS arm was significantly longer than that of the GC arm, indicating a better prognosis in the former. Additionally, the percentage of partial responses in the 123 patients enrolled in the GC arm was 15.0%; while the percentage of partial responses in the 119 patients enrolled in the GCS arm was 41.5%; thus, GCS was concluded to achieve a better disease control as compared to GC [16]. Therefore, GCS is used as one of the standard treatments for advanced BTC instead of GC. In the current case, because there was no history of triplet cytotoxic chemotherapeutic regimens like GCS at the local hospital at the time of diagnosis, GC was administered; however, GCS may have been a better treatment option, considering that the incidence of adverse events, except those related to S-1, did not differ significantly between the two arms of the phase III study. In the current case, CoCC showed many elements similar to ICC clinically, and required histopathological and immunohistochemical assessments as well as a special staining for mucin to differentiate it from ICC. When there are many ICC-like areas, combination therapy of gemcitabine and cisplatin can be expected to have efficiency similar to that in ICC. In addition, because CoCC is associated with the expression of cholangiocyte markers, such as CK7 and CK19, chemotherapy regimens generally used for ICC may be effective for CoCC [17].
| No. | Author (reference number), year | Age | Sex | Viral infection | Underlying liver disease | Localization of tumor | Size (cm) of tumor before chemotherapy | Size (cm) of tumor after chemotherapy | Purpose of chemotherapy | Administration method/regimen/total courses | Surgical treatment | Adjuvant chemotherapy | Outcome |
|-----|---------------------------------|-----|-----|-----------------|--------------------------|----------------------|---------------------------------------|--------------------------------------|-------------------------------|---------------------------------------------|------------------|-----------------------|---------|
| 1   | Nakayama [6], 2012             | 78  | M   | HCV             | nd                       | S4/S5                | 8.0 x                                 | 7.0 x                                | Downsizing chemotherapy         | Hepatic arterial infusion/gemcitabine and cisplatin/3 courses | Central bisegmentectomy | None                  | Being followed up for 3 months |
| 2   | Kawashima et al. [13], 2012    | 57  | F   | nd              | nd                       | S1/S5/S6             | 7.0 x                                | nd                                  | Neoadjuvant chemotherapy         | Intravenous/gemcitabine/2 courses | Right hepatectomy           | Gemcitabine         | Being followed up for 4 months |
| 3   | Current case                   | 59  | F   | HBV             | Chronic hepatitis        | S4/S5/S8             | 6.5                                  | 3.8                                 | Downsizing chemotherapy         | Intravenous/gemcitabine and cisplatin/11 courses | Extended left hepatectomy | 5-1                   | Being followed up for 14 months |

*nd not described, HBV Hepatitis B virus, HCV Hepatitis C virus, CoCC cholangiolocellular carcinoma*
Third, the overall prognosis for CoCC has not yet been clearly determined due to its low incidence, but several reviews have reported that the prognosis is comparatively better than that of ICC [3, 18, 19]. Ariizumi et al. reported that patients with CoCC showed favorable long-term survival after curative surgery; 28 cases of CoCC had a 5-year survival rate of 75% [3]. Komuta et al. reported that one of the independent risk factors for recurrence was a maximal tumor size of > 40 mm [1]. Although not limited to CoCC, including ICC, Chen et al. and Kusano et al. reported microvascular invasion as a risk factor for recurrence [18, 19]. In the current case, the diameter of the tumor was 45 mm after chemotherapy; microvascular invasion was also present; thus, we would expect the current case to have a high risk of recurrence. Although the effectiveness of adjuvant therapy for BTC has been shown, no standard adjuvant chemotherapy regimen has been established for patients with BTC or CoCC [20]. Additionally, although clinical trials (JCOG1202) are currently in progress and no results have been obtained, S-1 is considered to be a promising agent for postoperative adjuvant therapy in patients with BTC [21]. In the current case, considering the risk of recurrence, according to JCOG1202, S-1 as adjuvant chemotherapy was administered.

Conclusions

We report a rare case of locally advanced CoCC that had been diagnosed as unresectable, which was successfully treated with hepatectomy after downsizing chemotherapy. Downsizing chemotherapy with gemcitabine and cisplatin may be an effective treatment strategy for locally advanced CoCC. Further evidence is required to establish an optimal strategy for the treatment of locally advanced CoCC.

Abbreviations

CoCC: Cholangiolocellular carcinoma; ICC: Intrahepatic cholangiolocellular carcinoma; CT: Computed tomography; GC: Gemcitabine, cisplatin; RPHD: Right posterior hepatic duct; MRI: Magnetic resonance imaging; FDG18: 18F-fluorodeoxyglucose; PET/CT: Positron emission tomography/computed tomography; SUV: Standardized uptake value; UICC: Union for International Cancer Control; ICG: Indocyanine green; TC-99m GSA: Technetium-99m-galactosyl human serum albumin; HCC: Hepatocellular carcinoma; BTC: Biliary tract cancer; ESMO: European Society for Medical Oncology; GCS: Gemcitabine, cisplatin plus S-1.

Acknowledgements

We thank all staff members employed at Kagoshima University Hospital for treating and caring for the patient. We would like to express our gratitude to Dr. Mari Kirishima (Department of Pathology, Field of Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University) for her comments on the pathological diagnosis and discussion.

Authors’ contributions

YH and YK drafted the manuscript. SI, TI, YM, HK, KM, TA, and SN managed the perioperative course. YH, KT, and SU collected the data. TO supervised the writing of the manuscript. All authors discussed the manuscript content. All authors read and approved the final manuscript.

Funding

We declare that each author received no funding for this study.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8520, Japan. 2 Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Received: 21 December 2020 Accepted: 20 January 2021
Published online: 26 January 2021

References

1. Komuta M, Spee B, Vander Borght S, De Vos R, Vanlype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47(5):1544–56.
2. Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer. 1959;12(4):753–9.
3. Ariizumi S, Koteray Y, Kataegiri S, Nakano M, Nakamura Y, Saito A, et al. Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2014;21(5 Suppl 3):S451–8.
4. Okabayashi T, Shima Y, Morita S, Shimada Y, Sumiyoshi T, Sui K, et al. Liver function assessment using technetium 99m-galactosyl single-photon emission computed tomography/CT fusion imaging: a prospective trial. J Am Coll Surg. 2017;225:789–97.
5. Yamaguchi T, Seki T, Inokuchi R, Kawamura R, Murata M, Matsuizaki K, et al. S-1 monotherapy in a patient with cholangiolocellular carcinoma: a case report. Mol Clin Oncol. 2016;5:762–6.
6. Nakayama Y, Nakamura N, Ito T, Matsubayashi J, Yogo A, Kitou Y, et al. Resection of cholangiolocellular carcinoma successfully responding to neoadjuvant hepatic arterial infusion chemotherapy—report of a case. Gan To Kagaku Ryoho. 2012;39(7):1155–7.
7. Asayama Y, Tajima T, Okamoto D, Nishie A, Ishigami K, Ushijima Y, et al. Imaging of cholangiolocellular carcinoma of the liver. Eur J Radiol. 2010;75(1):e120–5.
8. Kozaka K, Matsu O, Kobayashi S, Koda W, Minami T, Kitao A, et al. Dynamic CT findings of cholangiolocellular carcinoma: correlation with angiography-assisted CT and histopathology. Abdom Radiol. 2017;42(3):861–9.
9. Fukukura Y, Hamaoue M, Fujiyoshi F, Sasaki M, Haruta K, Inoue H, et al. Cholangiolocellular carcinoma of the liver: CT and MR findings. J Comput Assist Tomogr. 2000;24(5):809–12.
10. Motosugi U, Ichikawa T, Nakajima H, Araki T, Matsuda M, Suzuki T, et al. Cholangiolocellular carcinoma of the liver: imaging findings. J Comput Assist Tomogr. 2009;33(5):682–8.
11. Shiota K, Taguchi J, Nakashima O, Nakashima M, Kojiri M. Clinicopathological study on cholangiolocellular carcinoma. Oncol Rep. 2001;8(2):263–8.
12. Suzumura K, Asano Y, Hirano T, Okada T, Uyama N, Aizawa N, et al. Synchronous double cancers of primary hepatocellular carcinoma and cholangiolocellular carcinoma: a case report. Surg Case Rep. 2016;2(1):139.
treated by neoadjuvant chemotherapy with gemcitabine followed by radical resection. Gan To Kagaku Ryoho. 2012;39(12):2113–5.

14. Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2010;4(4):395–7.

15. Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, Furukawa K, Takayashiki T, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–9.

16. Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol. 2018;29:205–70.

17. Ishii N, Suzuki H, Tsukagoshi M, Watanabe A, Kubo N, Araki K, et al. Giant cholangiolocellular carcinoma with early recurrence that was difficult to distinguish from cholangiocellular carcinoma: report of a case. Int Surg. 2015;100(6):1111–6.

18. Kusano H, Naito Y, Mihara Y, Kondo R, Ogasawara S, Akiba J, et al. Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma. Hepatol Res. 2020;50(1):84–91.

19. Chen J, He J, Deng M, Wu HY, Shi J, Mao L, et al. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Hum Pathol. 2017;64:118–27.

20. Belkouz A, Wilmink JW, Haj Mohammad N, Hagendoorn J, de Vos-Geelen J, Dejong CHC, et al. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Crit Rev Oncol Hematol. 2020;151:102975.

21. Nakachi K, Koriishi M, Ikeda M, Mizusawa J, Eba J, Okusaka T, et al. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, Ascot). Jpn J Clin Oncol. 2018;48(4):392–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.